In vivo Evaluation of Cenderitide-Eluting Stent (CES) II

Yingying Huang, Xu Wen Ng, Soon Ghim Lim, Horng Haur Chen, John C Jr. Burnett, Yin Chiang Freddy Boey, Subbu S. Venkatraman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The use of drug-eluting coronary stents has led to significant reduction in in-stent restenosis (ISR), but led to delayed endothelialization, necessitating the prolonged use of expensive anti-thrombotic drugs with their side-effects. Cenderitide (CD-NP) is a novel anti-proliferative chimeric peptide of semi-endothelial origin. Our previous work in vitro has demonstrated; that the smooth muscle cells were inhibited significantly more than endothelial cells which is the desirable feature of an anti-restenosis drug. This work reports the effects of implantation of a centeritide-eluting stent (CES) on ISR and endothelialization in an in vivo model. CESs were produced by coating bare metallic stents with CD-NP entrapped in biodegradable poly(ε-caprolactone) using an ultrasonic spray coater. A total of 32 stents were successfully implanted into 16 pigs, and all animal survived for 28 days. The plasma levels of CD-NP were significantly higher in the CES group than in the control group (bare metal stents and polymer-coated stent) at post-stenting, indicating the successful release of CD-NP from the stent in vivo. Furthermore, SEM analysis results showed the greater endothelial coverage of the stent struts, as well as between the struts in CES group. Moreover, histological results showed mild inflammation, and low fibrin score at 28 days. However, plasma cGMP (second messenger, cyclic 3′,5′ guanosine monophosphate) does not show a significant difference, and the CES is also unable to show significant difference in terms on neointimal area and stenosis, in comparison to BMS at 28 days.

Original languageEnglish (US)
Pages (from-to)432-441
Number of pages10
JournalAnnals of Biomedical Engineering
Volume44
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Stents
Struts
Plasmas
Endothelial cells
Peptides
Muscle
Animals

Keywords

  • Cenderitide (CD-NP)
  • In vivo
  • Natriuretic peptide
  • Stent

ASJC Scopus subject areas

  • Biomedical Engineering

Cite this

In vivo Evaluation of Cenderitide-Eluting Stent (CES) II. / Huang, Yingying; Ng, Xu Wen; Lim, Soon Ghim; Chen, Horng Haur; Burnett, John C Jr.; Boey, Yin Chiang Freddy; Venkatraman, Subbu S.

In: Annals of Biomedical Engineering, Vol. 44, No. 2, 01.02.2016, p. 432-441.

Research output: Contribution to journalArticle

Huang, Yingying ; Ng, Xu Wen ; Lim, Soon Ghim ; Chen, Horng Haur ; Burnett, John C Jr. ; Boey, Yin Chiang Freddy ; Venkatraman, Subbu S. / In vivo Evaluation of Cenderitide-Eluting Stent (CES) II. In: Annals of Biomedical Engineering. 2016 ; Vol. 44, No. 2. pp. 432-441.
@article{5b55dcc05253455b8b5cf11cedf30198,
title = "In vivo Evaluation of Cenderitide-Eluting Stent (CES) II",
abstract = "The use of drug-eluting coronary stents has led to significant reduction in in-stent restenosis (ISR), but led to delayed endothelialization, necessitating the prolonged use of expensive anti-thrombotic drugs with their side-effects. Cenderitide (CD-NP) is a novel anti-proliferative chimeric peptide of semi-endothelial origin. Our previous work in vitro has demonstrated; that the smooth muscle cells were inhibited significantly more than endothelial cells which is the desirable feature of an anti-restenosis drug. This work reports the effects of implantation of a centeritide-eluting stent (CES) on ISR and endothelialization in an in vivo model. CESs were produced by coating bare metallic stents with CD-NP entrapped in biodegradable poly(ε-caprolactone) using an ultrasonic spray coater. A total of 32 stents were successfully implanted into 16 pigs, and all animal survived for 28 days. The plasma levels of CD-NP were significantly higher in the CES group than in the control group (bare metal stents and polymer-coated stent) at post-stenting, indicating the successful release of CD-NP from the stent in vivo. Furthermore, SEM analysis results showed the greater endothelial coverage of the stent struts, as well as between the struts in CES group. Moreover, histological results showed mild inflammation, and low fibrin score at 28 days. However, plasma cGMP (second messenger, cyclic 3′,5′ guanosine monophosphate) does not show a significant difference, and the CES is also unable to show significant difference in terms on neointimal area and stenosis, in comparison to BMS at 28 days.",
keywords = "Cenderitide (CD-NP), In vivo, Natriuretic peptide, Stent",
author = "Yingying Huang and Ng, {Xu Wen} and Lim, {Soon Ghim} and Chen, {Horng Haur} and Burnett, {John C Jr.} and Boey, {Yin Chiang Freddy} and Venkatraman, {Subbu S.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s10439-015-1389-1",
language = "English (US)",
volume = "44",
pages = "432--441",
journal = "Annals of Biomedical Engineering",
issn = "0090-6964",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - In vivo Evaluation of Cenderitide-Eluting Stent (CES) II

AU - Huang, Yingying

AU - Ng, Xu Wen

AU - Lim, Soon Ghim

AU - Chen, Horng Haur

AU - Burnett, John C Jr.

AU - Boey, Yin Chiang Freddy

AU - Venkatraman, Subbu S.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The use of drug-eluting coronary stents has led to significant reduction in in-stent restenosis (ISR), but led to delayed endothelialization, necessitating the prolonged use of expensive anti-thrombotic drugs with their side-effects. Cenderitide (CD-NP) is a novel anti-proliferative chimeric peptide of semi-endothelial origin. Our previous work in vitro has demonstrated; that the smooth muscle cells were inhibited significantly more than endothelial cells which is the desirable feature of an anti-restenosis drug. This work reports the effects of implantation of a centeritide-eluting stent (CES) on ISR and endothelialization in an in vivo model. CESs were produced by coating bare metallic stents with CD-NP entrapped in biodegradable poly(ε-caprolactone) using an ultrasonic spray coater. A total of 32 stents were successfully implanted into 16 pigs, and all animal survived for 28 days. The plasma levels of CD-NP were significantly higher in the CES group than in the control group (bare metal stents and polymer-coated stent) at post-stenting, indicating the successful release of CD-NP from the stent in vivo. Furthermore, SEM analysis results showed the greater endothelial coverage of the stent struts, as well as between the struts in CES group. Moreover, histological results showed mild inflammation, and low fibrin score at 28 days. However, plasma cGMP (second messenger, cyclic 3′,5′ guanosine monophosphate) does not show a significant difference, and the CES is also unable to show significant difference in terms on neointimal area and stenosis, in comparison to BMS at 28 days.

AB - The use of drug-eluting coronary stents has led to significant reduction in in-stent restenosis (ISR), but led to delayed endothelialization, necessitating the prolonged use of expensive anti-thrombotic drugs with their side-effects. Cenderitide (CD-NP) is a novel anti-proliferative chimeric peptide of semi-endothelial origin. Our previous work in vitro has demonstrated; that the smooth muscle cells were inhibited significantly more than endothelial cells which is the desirable feature of an anti-restenosis drug. This work reports the effects of implantation of a centeritide-eluting stent (CES) on ISR and endothelialization in an in vivo model. CESs were produced by coating bare metallic stents with CD-NP entrapped in biodegradable poly(ε-caprolactone) using an ultrasonic spray coater. A total of 32 stents were successfully implanted into 16 pigs, and all animal survived for 28 days. The plasma levels of CD-NP were significantly higher in the CES group than in the control group (bare metal stents and polymer-coated stent) at post-stenting, indicating the successful release of CD-NP from the stent in vivo. Furthermore, SEM analysis results showed the greater endothelial coverage of the stent struts, as well as between the struts in CES group. Moreover, histological results showed mild inflammation, and low fibrin score at 28 days. However, plasma cGMP (second messenger, cyclic 3′,5′ guanosine monophosphate) does not show a significant difference, and the CES is also unable to show significant difference in terms on neointimal area and stenosis, in comparison to BMS at 28 days.

KW - Cenderitide (CD-NP)

KW - In vivo

KW - Natriuretic peptide

KW - Stent

UR - http://www.scopus.com/inward/record.url?scp=84959098839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959098839&partnerID=8YFLogxK

U2 - 10.1007/s10439-015-1389-1

DO - 10.1007/s10439-015-1389-1

M3 - Article

C2 - 26178873

AN - SCOPUS:84959098839

VL - 44

SP - 432

EP - 441

JO - Annals of Biomedical Engineering

JF - Annals of Biomedical Engineering

SN - 0090-6964

IS - 2

ER -